China CAR-T Cell

Presentation during EHA2022: All Oral presentations were presented between Friday, June 10 and Sunday, June 12 and is accessible for on-demand viewing from Monday, June 20 until Monday, August 15, 2022 on the Congress platform. CT103A, a fully human BCMA-directed CAR-T therapy, showed excellent safety and promising efficacy in the ongoing phase 1/2 FUMANBA-1 study (ChiCTR1800018137, […]

During The European Hematology Association (EHA), Dr. Peggy Lu from Lu Daopei Hospital gave a oral speech concerning CAR-T therapy based on CD7 for relapsed & refractory T cell hematologic malignancies. T cell malignant tumor is a kind of hematological tumor with high recurrence rate and mortality. The co expression of CD7 by CAR-T cells and malignant […]

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, ON June 3, 2022 announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase 1 clinical trial in the United States. […]

SAN FRANCISCO and SUZHOU, China, June 6, 2022  /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and […]

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant […]

For CAR-T therapy to make breakthroughs in solid tumors, many problems need to be solved. Among them, how to solve the problem of CAR-T entering the dense solid tumors is the most critical problem. By targeting new targets and continuing to track, many CAR-T clinical trials for the treatment of solid tumors have started in China, and it […]

A female patient from China was diagnosed as “multiple myeloma IgD-λ type III A” in 2018. The patient received a first-line treatment regimen based on bortezomib, and the efficacy evaluation was CR after 3 cycles. In October 2018 Monthly autologous hematopoietic stem cell transplantation was performed as consolidation therapy, followed by oral lenalidomide maintenance therapy. […]

A patient from Italy received CAR-T treatment for myeloma 8 months after her diagnosis. In October 2018, 66-year-old Cinty was diagnosed with “multiple myeloma, λ light chain type, ISS stage I” in Italy. Subsequently, she received 4 cycles of VTD chemotherapy, during which she developed a fracture of the lateral third of the clavicle and peripheral […]

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment […]

Accelerating the Advancement of Universal CAR-NK Cell Therapy Founded in 2014, iMBioRay is engaged in the treatment of tumors and immune diseases. In 2016, it focused on the development of innovative general-purpose off-the-shelf CAR-NK cell therapy. Through its original technology platform, it has developed a series of cell and antibody drugs, committed to In order to […]